Syntara (SNT) H1 2026 earnings summary

Executive summary

• Focused on clinical-stage drug development targeting extracellular matrix dysfunction, with lead candidate amsulostat advancing in myelofibrosis, MDS, and pancreatic cancer trials.

• Expanded clinical pipeline includes SNT-9465 for hypertrophic scars, SNT-6302 for keloid scars, and SNT-4728 for neuroinflammatory disorders.

• Received significant non-dilutive funding through government grants and R&D tax incentives, supporting ongoing clinical programs.

• Completed sale and separation of the mannitol respiratory business, with ongoing efforts to recover outstanding payments.

Financial highlights

• Net loss after tax for the half-year was $5.86 million, compared to $2.72 million for the same period last year.

• Total revenue and other income reached $3.28 million, mainly from R&D tax incentives and grants.

• Cash and cash equivalents at period end were $10.5 million, down from $15.1 million at the start of the period.

• Total liabilities decreased to $3.45 million from $5.43 million at the previous period end.

• Received $5.6 million R&D tax incentive refund during the period.

Outlook and guidance

• Multiple clinical trial readouts and regulatory milestones anticipated in 2026 across the pipeline.

• Continued focus on advancing amsulostat in multiple indications and expanding non-dilutive funding sources.